Almirall Aesthetics Takeover
This article was originally published in Scrip
Dermatology focused Almirall has announced that it will be exercising a call option to acquire 100% of aesthetics technology company ThermiGen LLC. Almirall plans to complete the acquisition by Jan. 31st 2016, with hopes to create a profile in the aesthetics market to strengthen its presence in derma.
You may also be interested in...
Sun Pharma has struck a licensing deal with Almirall for its late-stage psoriasis asset tildrakizumab, building on its recent clinical advancement and raising hopes of significant upsides for the Indian firm. The IL-23p19 inhibitor also adds to Almirall's broad derma portfolio amid the Spanish firm's acquisitive interest in the space.
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.